CAR-T treatment

Phase 2Cell therapy

FFirst Affiliated Hospital of Zhejiang University

CAR-T treatment is one of 25 biologic programs targeting Multiple Myeloma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple MyelomaActive, not recruiting

Multiple MyelomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Ninlaro

Takeda

Preclinical

18 2

Prolia

Amgen

Preclinical

5 3

Eliquis

Bristol-Myers Squibb

Preclinical

3 4

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

2 5

Adriamycin

GGynecologic Oncology Group

Preclinical

9 6

Oncovin

EEastern Cooperative Oncology Group

Preclinical

8 7

Intron a

Merck & Co.

Preclinical

—8

CAR-T treatment

FFirst Affiliated Hospital of Zhejiang University

Phase 2

2 9

Abecma

Bristol-Myers Squibb

Preclinical

4 10

Oblimersen Sodium

NNational Cancer Institute (NCI)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Multiple Myeloma

NCT06581640

Clinical

Trials by Indication[1]

Multiple Myeloma2 trials

B Cell Maturation Antigen（BMCA）-Targeted CAR-T for Refractory/Relapsed Multiple Myeloma

Unknown status·FFirst Affiliated Hospital of Zhejiang University·Phase 2·NCT03931421·30 enrolled

Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma

Recruiting·TThe First Affiliated Hospital of Xiamen University·Phase 2·NCT06581640·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for CAR-T treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CAR-T treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CAR-T treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — First Affiliated Hospital of Zhejiang University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: FFirst Affiliated Hospital of Zhejiang University

CAR-T treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Multiple Myeloma2 trials

References

Drug Info

Quick Facts

Related News